KeratoconusNCT04383301
Combined Corneal Wavefront-guided TPRK and ACXL Following ICRS Implantation in Management of Moderate Keratoconus
A study testing Intracorneal ring segment implantaion as the first stage and ACXL and wafe front guieded TPRK as the second stage in people with Keratoconus, run by Shaaban Elwan at 1 site in Saudi Arabia.
Trial summary
Background: Keratoconus leads to gradual progressive loss of vision in young and adult patients. For visual rehabilitation and to hinder keratoconus progressionthe investigators designed this study to help the keratoconus patients to improve and stabilize their vision. Read more about this study
- Who is it for?
- Ages 20 to 48 years
- Conditions the study is for
- Keratoconus
- What is being tested?
- Intracorneal ring segment implantaion as the first stage and ACXL and wafe front guieded TPRK as the second stage
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteSaudi Arabia
- Study dates
- 1 Oct 2018to 30 Apr 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 48 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adult patient with age > 20 years old and intolerant to contact lense use
- patients had moderate keratoconus (45-54 D in both meridians) without corneal scarring
- Central pachymetry ≥ 400 μm and if progression had been noted over the previous 6 months.
Who cannot join
- Patients with central or paracentral corneal scarring
- Central pachymetry <400 μm, systemic autoimmune disease
- History of herpetic keratitis, pregnancy, lactation, or severe dry eye syndrome.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking Following Intra Corneal Ring Segment Implantation in Management of Moderate Keratoconus
Background: Keratoconus leads to gradual progressive loss of vision in young and adult patients. For visual rehabilitation and to hinder keratoconus progressionthe investigators designed this study to help the keratoconus patients to improve and stabilize their vision.
Design: This is a prospective consecutive uncontrolled study.
Read more
Patients and Methods:
This study includes 36 eyes of 36 patients with moderate degree o keratoconus (KC) undergoing combined wave front guided transepithelial photorefractive keratectomy (TPRK) and accelerated corneal collagen crosslinking (ACXL) after intracorneal ring segment (ICRS) implantation. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent (MRSE), corneal indices based on Scheimpflug tomography, higher-order aberrations (HOAs) will be evaluated at baseline, after ICRS implantation, and at1, 3, 6, and 12 months after combined TPRK and CXL.
Read the detailed description
Patients and Methods:
This study conducted upon 36 eyes of 36 patients with moderate keratoconus who undergoing combined corneal wavefront-guided TPRK and accelerated corneal CXL at least 3 months after ICRS implantation in the period between October, 2018 and April 2020, at the Security Forces Hospital, Ophthalmology Department, Riyadh, Kingdom of Saudi Arabia. The study was approved by SFHP ethical board committee (IRB registraion number: 18-289-54) and was adhered to the tenets of the Declaration of Helsinki as well as followed good clinical practices. All patients provided informed written consent for the study and for publication. All included patients undergoing combined corneal wavefront guided TPRK and corneal ACXL at least 3 months after ICRS implantation. Grading of keratoconus was based on the Amsler Krumeich classification. Progression was defined as one or more of the following changes over a period of 6 months: an increase of ≥1.00 diopter (D) in maximal keratometry values, an increase of ≥1.00 D in manifest cylinder, and an increase of ≥ 0.50 D in MRSE.
Examinations and measurements:- At baseline, the preoperative examination included UDVA, CDVA, manifest and cycloplegic refraction, slit lamp biomicroscopy, tonometry, Pentacam camera, tomography, and dilated fundus examination using binocular ophthalmoscopy. If patient use contact lenses it should be stopped 3 weeks before exam date, and medical history, including any systemic diseases, were recorded. After ICRS implantation (before combined TPRK and ACXL), and at 1, 3, 6, and 12 months after combined TPRK and CXL, all patients undergoing complete ophthalmic examinations, which included examinations for UDVA and CDVA with a Snellen chart, manifest refraction (MR). The corneal indices measured at the 8-mm zone using the Scheimpflug tomography system with Pentacam camera (OCULUS- Netzteil Art., Pentacam HR, Germany), and for measuring changes in corneal aberrations, including HOAs, coma, and spherical aberrations, corneal wavefront analysis implemented using corneal topographic data with tomography (Sirius, SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Root mean square (RMS) values of the corneal HOAs, with analysis up to the 7th order by expanding the set of Zernike polynomials, were calculated. Any postoperative complications, corneal haze , wound healing time were estimated. Patients overall satisfaction for the procedure were asked at last follow up and all data were recorded.
Surgical technique:-
First step procedure:
Before the surgery, tetracaine hydrochloride 0.5% ophthalmic solution (Bausch \& Lomb, Minims) and moxifloxacin 0.5% (Vigamox, Alcon Co.) drops were instilled 3 times within a 5-minutes interval. The eyelids were prepared with antiseptic Chlorohexidine Gluconate 0.05% solution (Saudi Medical Solution Company). All patients undergoing femtosecond laser enabled ICRS implantation. An Intacs SK intra-corneal ring (6.0 mm optical zone; fixed arc length of 150∘; angulation 30∘) was implanted in the cornea. The ring segment thickness sizes were decided according to the nomogram provided by the manufacturer. The incision was placed at the steepest meridian and the depth of the ring tunel was set at 75-80% of the thinnest pachymetry reading. After surgery, a bandage contact lens (BIOMEDICS Evolution CL ocufilcon D 45%, water 55%) was placed to be removed after incision healing. Postoperative use of moxifloxacin 0.5% (Vigamox, Alcon Co.) eye drops 4 times/ day for two weeks, tobradex eye drops (Tobramycin 0.3%- dexamethasone 0.1%, Alcon Co.) with tapering dose for 1 month, and sodium hyaluronate 0.2% ( Hyfresh eye drops, Jamjoom Pharma Co.) eye drops QID for 3 months.
Second step procedure:
After at least 3 months with average 3.9 ± 2.2 and range (3-5) months from the ICRS implantation and when the mean keratometry stabilized and not decreased > 1 diopter from the previous visit, all patients were scheduled for combined corneal wavefront-guided TPRK and accelerated CXL. TPRK between the corneal ring segments were performed using Amaris excimer LASER 193 nm, version 750 S (Schwind eye-tech-solutions GmbH\& Co. KG, Mainparkstrasse, Kleinostheim, Germany. The ablation profile was planned using the integrated Optimized Refractive Keratectomy-Custom Ablation Manager software (Schwind eye-tech-solutions GmbH and Co KG). Using this software, ablation was planned based on clinical parameters, including manifest refraction, pachymetry, and corneal wavefront data (up to the 7th order aberrations) and topography obtained with the Sirius topographer. The maximum ablation depth was limited to ( 50- 60 micro m), and then mitomycin C 0.02% (MMC) was applied for 20 seconds to reduce postoperative haze followed by eye irrigation with balanced saline solution (BSS). Riboflavin 0.1 % with hydroxypropyl methylcellulose (Vibex Rapid; Avedro Inc., Waltham, MA, USA) is soaked onto the corneal surface for 10 minutes immediately after excimer laser ablation. Riboflavin solution were added at 2 minutes interval during the soaking process after which the eye was irrigated with cold BSS. After completion of soaking, Ultra viollet A exposure (wavelength: 365 nm) was performed for 10 minutes at an irradiance of 9 mW/cm², to give a total radiant exposure of 5.4 J/cm² and intermittent riboflavin drops application during radiant exposure.
At the end of the surgery a bandage contact lens was placed, and the same previous postoperative medications were used beside pain keller oral tablet was perscribed if needed.
Statistical Analysis:- The investigators recorded all patients' data in Microsoft Excel Sheet, then copied and analyzed using A Graph Pad Prism 8 program; Paired student's t-test was used for the UDVA \& CDVA means in log MAR values and for MRSE means. One way ANOVA was used for corneal indices. For all tests, a (P value < 0.05) was considered statistically significant.
- Conditions
- Keratoconus
- Being tested
- Intracorneal ring segment implantaion as the first stage, ACXL and wafe front guieded TPRK as the second stage
- Medical subject headings
- Keratoconus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intracorneal ring segment implantaion as the first stageProcedure or surgery
Also called ICRS
Intracorneal ring segment (ICRS)
ACXL and wafe front guieded TPRK as the second stageProcedure or surgery
Also called ACXL and TPRK
Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
| Study group | Role | What they receive |
|---|---|---|
| Intra corneal ring segment | Active comparator | Intra corneal ring segment implantation for moderate keratoconus patients Receives: Procedure: Intracorneal ring segment implantaion as the first stage |
| Corneal Wavefront-guided TPRK and ACXL | Active comparator | Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months Receives: Procedure: ACXL and wafe front guieded TPRK as the second stage |
What is being measured
The primary outcome is the main question the study is designed to answer.
UDVA
Uncorrected distance visual acuity
Measured: one year
CDVA
corrected distance visual acuity
Measured: one year
Refractive changes
Refractive changes in the mean sphere, mean cylinder and manifest refractive spherical equivalent (MRSE)
Measured: one year
Corneal Indices
All corneal indices including steep, flat, mean and maximal keratometries
Measured: 0ne year
Secondary outcomes (1)
HOA and coma aberrations
final root mean square (RMS) high orders aberrations (HOAs) and coma aberrations from baseline.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2020
- Study start1 Oct 2018
- Primary completion30 Apr 2020
- Study completion30 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for KeratoconusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- Intracorneal ring segment (ICRS) followed by accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shaaban Elwan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Shaaban Elwan, Minia University
- Investigators
- Ashraf M Bakhsh, MD, Principal investigator, Security Forces Hospital Program
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04383301
- Sponsor's protocol ID
- Minia University & SFH-2
- Status last verified
- May 2020
- First submitted
- 7 May 2020
- Last updated
- 13 May 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Al-Tuwairqi WS, Osuagwu UL, Razzouk H, Ogbuehi KC. One-Year Clinical Outcomes of a Two-Step Surgical Management for Keratoconus-Topography-Guided Photorefractive Keratectomy/Cross-Linking After Intrastromal Corneal Ring Implantation. Eye Contact Lens. 2015 Nov;41(6):359-66. doi: 10.1097/ICL.0000000000000135.
PubMed 25839343Lee H, Kang DSY, Ha BJ, Choi JY, Kim EK, Seo KY, Kim TI. Visual rehabilitation in moderate keratoconus: combined corneal wavefront-guided transepithelial photorefractive keratectomy and high-fluence accelerated corneal collagen cross-linking after intracorneal ring segment implantation. BMC Ophthalmol. 2017 Dec 29;17(1):270. doi: 10.1186/s12886-017-0666-1.
PubMed 29284455Koh IH, Seo KY, Park SB, Yang H, Kim I, Kim JS, Hwang DG, Nam SM. One-Year Efficacy and Safety of Combined Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-Linking after Intacs SK Intracorneal Ring Segment Implantation in Moderate Keratoconus. Biomed Res Int. 2019 Jul 8;2019:7850216. doi: 10.1155/2019/7850216. eCollection 2019.
PubMed 31360724
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking Following Intra Corneal Ring Segment Implantation in Management of Moderate Keratoconus
- ClinicalTrials.gov ID
- NCT04383301
- Acronym / sponsor ID
- Minia University & SFH-2
- Conditions
- Keratoconus
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Shaaban ElwanUniversity, hospital or other
- Study start
- 1 Oct 2018 (actual)
- Primary completion
- 30 Apr 2020 (actual)
- Study completion
- 30 Apr 2020 (actual)
- First posted
- 12 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Keratoconus leads to gradual progressive loss of vision in young and adult patients. For visual rehabilitation and to hinder keratoconus progressionthe investigators designed this study to help the keratoconus patients to improve and stabilize their vision.
Design: This is a prospective consecutive uncontrolled study.
Patients and Methods:
This study includes 36 eyes of 36 patients with moderate degree o keratoconus (KC) undergoing combined wave front guided transepithelial photorefractive keratectomy (TPRK) and accelerated corneal collagen crosslinking (ACXL) after intracorneal ring segment (ICRS) implantation. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent (MRSE), corneal indices based on Scheimpflug tomography, higher-order aberrations (HOAs) will be evaluated at baseline, after ICRS implantation, and at1, 3, 6, and 12 months after combined TPRK and CXL.
Detailed description
Patients and Methods:
This study conducted upon 36 eyes of 36 patients with moderate keratoconus who undergoing combined corneal wavefront-guided TPRK and accelerated corneal CXL at least 3 months after ICRS implantation in the period between October, 2018 and April 2020, at the Security Forces Hospital, Ophthalmology Department, Riyadh, Kingdom of Saudi Arabia. The study was approved by SFHP ethical board committee (IRB registraion number: 18-289-54) and was adhered to the tenets of the Declaration of Helsinki as well as followed good clinical practices. All patients provided informed written consent for the study and for publication. All included patients undergoing combined corneal wavefront guided TPRK and corneal ACXL at least 3 months after ICRS implantation. Grading of keratoconus was based on the Amsler Krumeich classification. Progression was defined as one or more of the following changes over a period of 6 months: an increase of ≥1.00 diopter (D) in maximal keratometry values, an increase of ≥1.00 D in manifest cylinder, and an increase of ≥ 0.50 D in MRSE.
Examinations and measurements:- At baseline, the preoperative examination included UDVA, CDVA, manifest and cycloplegic refraction, slit lamp biomicroscopy, tonometry, Pentacam camera, tomography, and dilated fundus examination using binocular ophthalmoscopy. If patient use contact lenses it should be stopped 3 weeks before exam date, and medical history, including any systemic diseases, were recorded. After ICRS implantation (before combined TPRK and ACXL), and at 1, 3, 6, and 12 months after combined TPRK and CXL, all patients undergoing complete ophthalmic examinations, which included examinations for UDVA and CDVA with a Snellen chart, manifest refraction (MR). The corneal indices measured at the 8-mm zone using the Scheimpflug tomography system with Pentacam camera (OCULUS- Netzteil Art., Pentacam HR, Germany), and for measuring changes in corneal aberrations, including HOAs, coma, and spherical aberrations, corneal wavefront analysis implemented using corneal topographic data with tomography (Sirius, SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Root mean square (RMS) values of the corneal HOAs, with analysis up to the 7th order by expanding the set of Zernike polynomials, were calculated. Any postoperative complications, corneal haze , wound healing time were estimated. Patients overall satisfaction for the procedure were asked at last follow up and all data were recorded.
Surgical technique:-
First step procedure:
Before the surgery, tetracaine hydrochloride 0.5% ophthalmic solution (Bausch \& Lomb, Minims) and moxifloxacin 0.5% (Vigamox, Alcon Co.) drops were instilled 3 times within a 5-minutes interval. The eyelids were prepared with antiseptic Chlorohexidine Gluconate 0.05% solution (Saudi Medical Solution Company). All patients undergoing femtosecond laser enabled ICRS implantation. An Intacs SK intra-corneal ring (6.0 mm optical zone; fixed arc length of 150∘; angulation 30∘) was implanted in the cornea. The ring segment thickness sizes were decided according to the nomogram provided by the manufacturer. The incision was placed at the steepest meridian and the depth of the ring tunel was set at 75-80% of the thinnest pachymetry reading. After surgery, a bandage contact lens (BIOMEDICS Evolution CL ocufilcon D 45%, water 55%) was placed to be removed after incision healing. Postoperative use of moxifloxacin 0.5% (Vigamox, Alcon Co.) eye drops 4 times/ day for two weeks, tobradex eye drops (Tobramycin 0.3%- dexamethasone 0.1%, Alcon Co.) with tapering dose for 1 month, and sodium hyaluronate 0.2% ( Hyfresh eye drops, Jamjoom Pharma Co.) eye drops QID for 3 months.
Second step procedure:
After at least 3 months with average 3.9 ± 2.2 and range (3-5) months from the ICRS implantation and when the mean keratometry stabilized and not decreased > 1 diopter from the previous visit, all patients were scheduled for combined corneal wavefront-guided TPRK and accelerated CXL. TPRK between the corneal ring segments were performed using Amaris excimer LASER 193 nm, version 750 S (Schwind eye-tech-solutions GmbH\& Co. KG, Mainparkstrasse, Kleinostheim, Germany. The ablation profile was planned using the integrated Optimized Refractive Keratectomy-Custom Ablation Manager software (Schwind eye-tech-solutions GmbH and Co KG). Using this software, ablation was planned based on clinical parameters, including manifest refraction, pachymetry, and corneal wavefront data (up to the 7th order aberrations) and topography obtained with the Sirius topographer. The maximum ablation depth was limited to ( 50- 60 micro m), and then mitomycin C 0.02% (MMC) was applied for 20 seconds to reduce postoperative haze followed by eye irrigation with balanced saline solution (BSS). Riboflavin 0.1 % with hydroxypropyl methylcellulose (Vibex Rapid; Avedro Inc., Waltham, MA, USA) is soaked onto the corneal surface for 10 minutes immediately after excimer laser ablation. Riboflavin solution were added at 2 minutes interval during the soaking process after which the eye was irrigated with cold BSS. After completion of soaking, Ultra viollet A exposure (wavelength: 365 nm) was performed for 10 minutes at an irradiance of 9 mW/cm², to give a total radiant exposure of 5.4 J/cm² and intermittent riboflavin drops application during radiant exposure.
At the end of the surgery a bandage contact lens was placed, and the same previous postoperative medications were used beside pain keller oral tablet was perscribed if needed.
Statistical Analysis:- The investigators recorded all patients' data in Microsoft Excel Sheet, then copied and analyzed using A Graph Pad Prism 8 program; Paired student's t-test was used for the UDVA \& CDVA means in log MAR values and for MRSE means. One way ANOVA was used for corneal indices. For all tests, a (P value < 0.05) was considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Intracorneal ring segment (ICRS) followed by accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
| Arm | Type | Receives |
|---|---|---|
| Intra corneal ring segment | Active comparator | Procedure: Intracorneal ring segment implantaion as the first stageIntra corneal ring segment implantation for moderate keratoconus patients |
| Corneal Wavefront-guided TPRK and ACXL | Active comparator | Procedure: ACXL and wafe front guieded TPRK as the second stageCombined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months |
Who may qualify
- Ages
- 20 to 48 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Adult patient with age > 20 years old and intolerant to contact lense use
- patients had moderate keratoconus (45-54 D in both meridians) without corneal scarring
- Central pachymetry ≥ 400 μm and if progression had been noted over the previous 6 months.
Key exclusion criteria (3 listed)
- Patients with central or paracentral corneal scarring
- Central pachymetry <400 μm, systemic autoimmune disease
- History of herpetic keratitis, pregnancy, lactation, or severe dry eye syndrome.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intracorneal ring segment implantaion as the first stageAlso: ICRSIntracorneal ring segment (ICRS) | Procedure or surgery | Intra corneal ring segment |
| ACXL and wafe front guieded TPRK as the second stageAlso: ACXL and TPRKAccelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK) | Procedure or surgery | Corneal Wavefront-guided TPRK and ACXL |
Primary outcome
UDVA
Time frame: one year
Uncorrected distance visual acuity
CDVA
Time frame: one year
corrected distance visual acuity
Refractive changes
Time frame: one year
Refractive changes in the mean sphere, mean cylinder and manifest refractive spherical equivalent (MRSE)
Corneal Indices
Time frame: 0ne year
All corneal indices including steep, flat, mean and maximal keratometries
1 secondary outcome
HOA and coma aberrations
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2020.
- Background: PubMed 25839343Al-Tuwairqi WS, Osuagwu UL, Razzouk H, Ogbuehi KC. One-Year Clinical Outcomes of a Two-Step Surgical Management for Keratoconus-Topography-Guided Photorefractive Keratectomy/Cross-Linking After Intrastromal Corneal Ring Implantation. Eye Contact Lens. 2015 Nov;41(6):359-66. doi: 10.1097/ICL.0000000000000135.
- Background: PubMed 29284455Lee H, Kang DSY, Ha BJ, Choi JY, Kim EK, Seo KY, Kim TI. Visual rehabilitation in moderate keratoconus: combined corneal wavefront-guided transepithelial photorefractive keratectomy and high-fluence accelerated corneal collagen cross-linking after intracorneal ring segment implantation. BMC Ophthalmol. 2017 Dec 29;17(1):270. doi: 10.1186/s12886-017-0666-1.
- Background: PubMed 31360724Koh IH, Seo KY, Park SB, Yang H, Kim I, Kim JS, Hwang DG, Nam SM. One-Year Efficacy and Safety of Combined Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-Linking after Intacs SK Intracorneal Ring Segment Implantation in Moderate Keratoconus. Biomed Res Int. 2019 Jul 8;2019:7850216. doi: 10.1155/2019/7850216. eCollection 2019.
- Individual participant dataSharing planned: No
Related trials for Keratoconus
RecruitingObservational study
UNITY DX Cornea Study
Tomography
Not yet recruiting
Performance Evaluation of the OCUTOP Hand-held Corneal Topographer
Corneal Topography, Dry Eye Syndromes
Recruiting
Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus
Keratoconus, Presbyopia
RecruitingObservational study
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Keratoconus, Ectasia
Enrolling by invitationObservational study
Corneal Biomechanical Analysis Using Brillouin Microscopy
Keratoconus, Keratoconus, Unstable
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ashraf M Bakhsh, MD principal investigator
Security Forces Hospital Program
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intracorneal ring segment implantaion as the first stage and ACXL and wafe front guieded TPRK as the second stage in people with Keratoconus, run by Shaaban Elwan at 1 site in Saudi Arabia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
UDVA (time frame: one year). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04383301, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2020.